---
title: "Novo Nordisk will significantly reduce the price of its weight loss drug in the U.S. next year, with a maximum reduction of 50%"
description: "Novo Nordisk announced that it will unify the monthly price of the semaglutide series of drugs in the United States to $675, a reduction of up to 50%, effective January next year, aimed at addressing "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276745048.md"
published_at: "2026-02-24T13:55:38.000Z"
---

# Novo Nordisk will significantly reduce the price of its weight loss drug in the U.S. next year, with a maximum reduction of 50%

> Novo Nordisk announced that it will unify the monthly price of the semaglutide series of drugs in the United States to $675, a reduction of up to 50%, effective January next year, aimed at addressing competition and market pressure from Eli Lilly. Following the announcement, U.S. stocks fell 3% in pre-market trading, having already dropped 19% this week due to poor new drug data. The price reduction mainly benefits insured individuals with high deductible plans and is unrelated to negotiated discounts with Medicare

Novo Nordisk announced a significant reduction in the prices of its star weight loss drugs Wegovy and Ozempic in the U.S. market, with the monthly price of the semaglutide series of drugs unified at $675, a reduction of up to 50%. The new pricing will take effect on January 1 next year. This move marks a major shift in the Danish pharmaceutical company's competitive strategy in the obesity market.

Following the announcement, Novo Nordisk's U.S. stock fell 3% in pre-market trading, while Eli Lilly's stock briefly dropped over 4%. Notably, **Novo Nordisk just released another set of disappointing trial data for its next-generation drug CagriSema on Monday, leading to a cumulative stock decline of about 19%.** The price reduction decision comes against this backdrop, further intensifying market concerns.

This price cut is Novo Nordisk's proactive response after losing its leading position in the obesity market. Eli Lilly's competing product Zepbound is currently priced at $1,086.37 per month, and with Novo Nordisk's unified pricing at $675, it creates a significant price advantage.

Jamey Millar, head of Novo Nordisk's U.S. operations, stated, **this price reduction will not have a direct impact on the company's net sales, but he is optimistic about gaining payer recognition.** Millar previously worked at Optum Rx, a pharmacy benefit management organization under UnitedHealth Group, and is well-versed in U.S. drug pricing strategies. He said:

> “Payers have previously called for lower drug prices, and I am confident they will accept and welcome these lower prices.”

## Patients with High Deductible Plans Benefit the Most

This price reduction targets wholesale procurement costs, and this price is the public price, not reflecting the complex discount and rebate system in the U.S. Under commercial insurance coverage, patients' out-of-pocket costs for Zepbound and Wegovy can currently be as low as $25 per month.

Jamey Millar pointed out that **this price reduction will have the most significant impact on individuals enrolled in high deductible insurance plans.** In such plans, patients' out-of-pocket costs are more closely related to drug prices. Additionally, individuals enrolled in plans with coinsurance design (where patients only pay a certain percentage of the listed price) will also benefit.

According to the Kaiser Family Foundation (KFF) Employer Health Benefits Survey, about one-third of employees covered by employer insurance joined high deductible health plans paired with personal health savings accounts last year. However, among surveyed large companies, the proportion covering GLP-1 weight loss drugs like Wegovy is less than half.

This price adjustment will take effect simultaneously with the discounts obtained from negotiations with the U.S. government regarding Medicare. Millar emphasized that the two price reduction measures are independent and unrelated

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [NVOX.US - Defiance Daily Target 2X Long NVO ETF](https://longbridge.com/en/quote/NVOX.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)
- [LLYX.US - Defiance Daily Target 2X Long LLY ETF](https://longbridge.com/en/quote/LLYX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| “彻底失望”！德银首次下调诺和诺德评级 | 德意志银行首次下调诺和诺德股票评级至 “持有”，因其减肥药 CagriSema 在临床试验中表现不佳，导致市场抛售，股价暴跌 16%。摩根大通也下调评级并大幅削减销售预期，华尔街对该股的看涨比例降至数年最低，显示出对诺和诺德中期前景的悲观情 | [Link](https://longbridge.com/en/news/276727300.md) |
| 美股夜盘异动：诺和诺德夜盘跌 3.68%，减肥药试验失利与目标价下调双重打击市场信心 | 诺和诺德公司夜盘跌 3.68%；礼来夜盘跌 0.24%，成交额达到 2.19 百万美元；辉瑞夜盘跌 0.15%，成交额达到 57.95 万美元；如瑞迪博士夜盘跌 1.02%，成交额达到 16.6 万美元。 | [Link](https://longbridge.com/en/news/276701324.md) |
| 期权热点｜周一 NVO 大跌 16%，部分看跌期权飙升 6775% | 美东时间 02 月 23 日，诺和诺德公司期权总成交 316590 张，看涨期权占比 57%，看跌期权占比 42%。 | [Link](https://longbridge.com/en/news/276681569.md) |
| “彻底失望”！德银首次下调诺和诺德评级 | 诺和诺德关键减肥药 CagriSema 临床不及礼来，引发罕见降级潮：德银五年来首降评级，摩根大通下调至 “中性” 并砍销售预期 63%。股价周一暴跌 16%，目前仅 37% 分析师给予 “买入” 评级。市场焦点转向 ziltivekima | [Link](https://longbridge.com/en/news/276726950.md) |
| 礼来升级 Zepbound 巩固优势、一支用整月！诺和诺德新药临床失利股价暴跌 | 礼来周一推出 Zepbound 多剂量 KwikPen 注射装置，患者仅需一支笔即可完成一个月四次给药，最低月价 299 美元，并已获 FDA 批准扩展标签。受此消息提振，礼来股价盘中涨超 5%。与此同时，竞争对手诺和诺德的下一代减肥药 C | [Link](https://longbridge.com/en/news/276630276.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.